Trial reportOral diseases2025
Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial.
Trial report in Oral diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Diagnostic accuracy of HPV DNA in oral gargle and rinse samples for Head and neck squamous cell carcinoma: A systematic review and meta-analysis.The Japanese dental science review · 2026Review
- Oral Microbial and Metabolic Alterations in Patients With Oral Lichen Planus Concomitant With Type 2 Diabetes Mellitus.MicrobiologyOpen · 2026Observational
- Artificial intelligence and oral microbiome: Reshaping the diagnostic and therapeutic paradigm of OSCC.Clinical and translational medicine · 2026Review
- Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology.Journal of xenobiotics · 2026Review
- Trehalose Exerts Selective Cytotoxicity Against Tongue Squamous Cell Carcinoma Cells While Exhibiting Limited Cytotoxicity Toward Normal Oral Squamous Cells.OncoTargets and therapy · 2026Article
- Non-Invasive Techniques for Early Detection of Oral Squamous Cell Carcinoma: A Narrative Review.Cancer management and research · 2026Review
- Overexpression of miR-516a-5p Promotes Erosive Oral Lichen Planus: In Vitro Study Based on Bioinformatics Analyses.Clinical and experimental dental research · 2025Article
- Recent advances in oral cryotherapy for the management of anticancer therapy-induced oral mucositis.Future science OA · 2025Review
- Genetic and Epigenetic Biomarkers for the Early Oral Cancerization Risk in Periodontitis Patients.Current issues in molecular biology · 2025Review
- C-X-C motif chemokine ligand 1 derived from oral squamous cell carcinoma promotes cancer-associated fibroblast differentiation and tumor growth.Molecular biomedicine · 2025Article
- Natural Strategies for Dental Hard-Tissue Remineralization: A Scoping Review of Galla Chinensis and Its Dual Anticaries Action.Clinical, cosmetic and investigational dentistry · 2025Review
- Dupilumab-Induced Generalized Lichen Planus: A Case Report.Journal of inflammation research · 2025Article
- Comprehensive Analysis of lncRNA/circRNAs-miRNA-mRNA Networks of Oral Lichen Planus.Journal of inflammation research · 2025Article
- Integrative multi-omics analysis-based Mendelian randomization identifies association of DNA repair-related genes with oral cancer.Cancer biomarkers : section A of Disease markersArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
objectiveTo examine the impact of fluocinonide 0.05% gel formulation for the topical treatment of oral lichen planus (OLP).
methodsThrough an RCT design, 47 patients with OLP were randomly allocated for topical OLP treatment with fluocinonide 0.05% (n = 23) or placebo (n = 24). Patients were examined for OLP symptoms, signs, disease severity, and extension score changes over 6-month follow-up.
resultsAfter 6 months, in comparison with placebo, patients treated with fluocinonide experienced a significant reduction of OLP symptoms (p = 0.024), signs (p = 0.014), and OLP extension score (p = 0.028). The two-way ANOVA estimation models revealed that treatment with fluocinonide determined, at 6 months, a positive significant effect on the reduced OLP signs (p = 0.017), OLP symptoms (p = 0.026), and OLP extension score (p = 0.028). The multivariate regression analysis highlighted that anxiety, stress, and depression were significant predictors of every analyzed OLP outcome (p < 0.05 for each parameter) and that patients who had baseline anxiety, depression, and stress gained more benefits from fluocinonide at 6-month follow-up.
conclusionsTopical fluocinonide 0.05% was more efficacious compared to placebo in reducing OLP outcomes at 6-month follow-up. Anxiety, depression, and stress were significant predictors of OLP outcomes and positively impacted the treatment with fluocinonide at 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.